nafamostat has been researched along with Carcinoma, Non-Small Cell Lung in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Damalanka, VC | 1 |
| Voss, JJLP | 1 |
| Mahoney, MW | 1 |
| Primeau, T | 1 |
| Li, S | 1 |
| Klampfer, L | 1 |
| Janetka, JW | 1 |
1 other study available for nafamostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Discovery; Hepatocyte Growth Fact | 2021 |